These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38910302)

  • 1. Role of Inositol-Requiring Enzyme 1 and Autophagy in the Pro-Fibrotic Mechanism Underlying Graves' Orbitopathy.
    Lee CE; Kim JY; Yoon JS; Ko J
    Yonsei Med J; 2024 Jul; 65(7):397-405. PubMed ID: 38910302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
    Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
    Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
    [No Abstract]   [Full Text] [Related]  

  • 3. PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis.
    Ko J; Kim JY; Kyoung Chae M; Jig Lee E; Sook Yoon J
    J Mol Endocrinol; 2021 May; 66(4):313-323. PubMed ID: 33870911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic role of histone deacetylase inhibition in an
    Byeon HJ; Choi SH; Kikkawa DO; Ko J; Yoon JS
    Mol Med Rep; 2024 Dec; 30(6):. PubMed ID: 39329199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy is involved in the initiation and progression of Graves' orbitopathy.
    Yoon JS; Lee HJ; Chae MK; Lee EJ
    Thyroid; 2015 Apr; 25(4):445-54. PubMed ID: 25687157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy.
    Jang SY; Park SJ; Chae MK; Lee JH; Lee EJ; Yoon JS
    Br J Ophthalmol; 2018 Mar; 102(3):407-414. PubMed ID: 29101123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
    Byeon HJ; Kim JY; Ko J; Lee EJ; Don K; Yoon JS
    PLoS One; 2020; 15(8):e0237015. PubMed ID: 32760098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
    Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
    Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosine-1-Phosphate Mediates Fibrosis in Orbital Fibroblasts in Graves' Orbitopathy.
    Ko J; Chae MK; Lee JH; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2544-2553. PubMed ID: 28492873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy.
    Jang SY; Choi SH; Kikkawa D; Lee EJ; Yoon JS
    PLoS One; 2021; 16(8):e0255344. PubMed ID: 34383782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of Targeting Periostin in the Treatment of Graves' Orbitopathy.
    Jang SY; Kim J; Park JT; Liu CY; Korn BS; Kikkawa DO; Lee EJ; Yoon JS
    Front Endocrinol (Lausanne); 2022; 13():900791. PubMed ID: 35707463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of binding immunoglobulin protein (BiP) in Graves' orbitopathy pathogenesis.
    Ko J; Kim JY; Lee EJ; Yoon JS
    J Mol Endocrinol; 2021 Jan; 66(1):71-81. PubMed ID: 33112798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biomarkers of Graves' ophthalmopathy.
    Longo CM; Higgins PJ
    Exp Mol Pathol; 2019 Feb; 106():1-6. PubMed ID: 30414981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients.
    Ekronarongchai S; Palaga T; Saonanon P; Pruksakorn V; Hirankarn N; van Hagen PM; Dik WA; Virakul S
    Thyroid; 2021 Oct; 31(10):1566-1576. PubMed ID: 34235979
    [No Abstract]   [Full Text] [Related]  

  • 15. Ceruloplasmin regulating fibrosis in orbital fibroblasts provides a novel therapeutic target for Graves' orbitopathy.
    Cao J; Qi X; Wang N; Chen Y; Xie B; Ma C; Chen Z; Xiong W
    J Endocrinol Invest; 2023 Oct; 46(10):2005-2016. PubMed ID: 36849849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts.
    Guo Y; Li H; Chen X; Yang H; Guan H; He X; Chen Y; Pokharel S; Xiao H; Li Y
    J Clin Endocrinol Metab; 2020 Jun; 105(6):1906-17. PubMed ID: 32249902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentraxin 3 mediates inflammation and adipogenesis in Graves' orbitopathy pathogenesis.
    Kim MS; Park HY; Choi SH; Chang EJ; Ko J; Yoon JS
    J Mol Endocrinol; 2024 Nov; 73(4):. PubMed ID: 39283923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
    Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
    Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
    Ko J; Kim JY; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy.
    Yoon JS; Chae MK; Jang SY; Lee SY; Lee EJ
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5921-9. PubMed ID: 22871832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.